Last reviewed · How we verify

NCT06237907

Pyroptosis and Ferroptosis in the Pathophysiology of Lymphedema

Status unknown Last updated 2 February 2024
What this trial tests

trial testing Patients underwent lymphedema surgery in Lymphedema in 120 participants. Status unknown.

Timeline
20 September 2023
Primary endpoint
20 September 2024
12 January 2026

Quick facts

Lead sponsorChang Gung Memorial Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment120
Start date20 September 2023
Primary completion20 September 2024
Estimated completion12 January 2026
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

Chang Gung Memorial Hospital

Who can join

Adults 20 to 100, any sex, with Lymphedema. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The project aims to compare the differences in the expression of cell death through apoptosis and iron-dependent cell death after the reduction of edema symptoms following lymphedema surgery in patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. In defence of ferroptosis.
    Alves F, Lane D, Nguyen TPM, Bush AI, et al · · 2025 · cited 75× · PMID 39746918 · DOI 10.1038/s41392-024-02088-5

Verify or expand the search:

Other recruiting trials for Lymphedema

Currently open trials in the same condition.

Other Chang Gung Memorial Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06237907.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing